MERCK & CO., INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 129.9 USD | +0.27% |
|
+1.18% | +19.03% |
| 04:44pm | Merck Says Health Canada Approve Keytruda Combination in Biliary Tract Carcinoma | MT |
| 03:21pm | Sector Update: Health Care Stocks Steady Pre-Bell Thursday | MT |
Presenter SpeechAndrew Baum (Analysts)So delighted to introduce our next speaker, Dr. Marjorie...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
129.6
USD
Average target price
141.6
USD
Spread / Average Target
+9.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.03% | 328B | |
| +32.59% | 698B | |
| +26.51% | 568B | |
| -4.62% | 358B | |
| +3.49% | 283B | |
| +16.34% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +8.16% | 165B | |
| -3.25% | 160B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Transcript : Merck & Co., Inc. Presents at Citi 18th Annual BioPharma Conference, Sep-06-2023 01